1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Gujarat Terce Laboratories Limited

Gujarat Terce Laboratories Limited

BBSE:GUJTERC
36.91
INR
+2.22
(+6.40%)
2.67EPS
13.34P/E
280.49MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
38.87
35.69
33.68
34.08
39.1
41.82
50.6
33.93
54.09
63.05
64.65
67.65
63.06
58.96
Basic EPS, GAAP
0.32
0.12
-0.91
-0.02
0.36
0.58
0.37
-3.4
1.18
-2.25
0.33
-1.32
2.92
2.7
Free Cash Flow per Basic Share
0.4
1
0.22
0.33
6.17
-0.83
-2.79
-0.9
-3.45
-0.05
3.4
4.12
2.24
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
14.74
14.87
13.96
13.55
14.02
14.6
14.97
10.33
11.5
9.25
9.58
8.73
12.49
- -
Tangible Book Value per Share
14.74
14.87
13.96
13.55
14.02
14.6
14.97
10.33
11.5
9.25
9.58
8.73
12.49
- -
Basic Weighted Avg Shares
7
7
7
7
7
7
7
7
7
7
7
7
8
8
Sales/Revenue/Turnover
288
265
250
253
290
310
375
252
401
468
480
502
475
456
Operating Margin (%)
2.15
2.35
-0.11
-0.43
0.48
0.89
1.18
-10.31
3.47
-5.26
1.93
7.01
7.12
6.23
Depreciation Expense
3
2
2
2
2
2
2
2
3
4
4
4
4
4
Net Income, GAAP
2
1
-7
- -
3
4
3
-25
9
-17
2
-10
22
21
Effective Tax Rate (%)
29.49
68.89
- -
168.67
16.75
- -
36.64
- -
- -
- -
55.24
128.86
27.39
29.65
Profit Margin (%)
0.83
0.34
-2.7
-0.06
0.93
1.39
0.74
-10.01
2.17
-3.57
0.51
-1.95
4.64
4.58
Working Capital
85
89
69
65
24
26
26
3
23
-6
-9
-6
35
- -
LT Debt
57
55
55
55
2
1
2
4
23
15
9
3
- -
- -
Total Equity
109
110
104
101
104
108
111
77
85
69
71
65
97
- -
Return on Invested Capital (%)
1.11
0.46
- -
-0.07
0.85
- -
2.35
- -
- -
- -
3.21
-10.98
22.76
- -
Return on Capital (%)
2.61
1.12
- -
-1.22
3.05
- -
3.47
- -
- -
- -
4.18
-11.78
25.11
- -
Return on Common Equity (%)
2.23
0.83
-6.3
-0.15
2.65
4.07
2.52
-26.85
10.77
-21.71
3.49
-14.41
27.17
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
13
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
339
241
280

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
144
- -
Cash, Cash Equivalents & STI
- -
42
- -
Accounts Receivable, Net
- -
49
- -
Inventories
- -
37
- -
Total Current Liabilities
- -
109
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
13
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.29%
7.34%
50.18%
Free Cash Flow
-497.71%
-1,375.82%
-44.94%
Net Income, GAAP
-438.29%
-273.54%
-324.98%
Sales/Revenue/Turnover
8.86%
15.55%
-5.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
119
133
127
123
502
2026
109
129
123
114
475
2027
90
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.1
2
1.36
-4.57
-1.32
2026
-0.06
1.89
0.95
0.13
2.92
2027
-0.23
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Aalap Natubhai Prajapati
Full Time Employees
235
Sector
Health technology
Industry
Pharmaceuticals: major
Address
D/ 801 - 802 & 1202, The First Ahmedabad GU India 380015
IPO Date
Jan 28, 1993
Website
gujaratterce.in
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Gujarat Terce Laboratories Limited develops, manufactures, markets, and distributes a broad portfolio of pharmaceutical medicines and healthcare products across key therapeutic areas including respiratory system disorders, antibiotics, pain therapy, gastrointestinal therapy, gynaecological products, nutraceuticals, and ayurvedic formulations; core offerings encompass tablets such as Acolate-M (levocetirizine di-HCl 5 mg + montelukast sodium 10 mg), Aziter 500 (azithromycin 500 mg), Algin-P (aceclofenac 100 mg + paracetamol 325 mg), and OMRON Plus Syrup (ferrous ascorbate eq. to elemental iron 30 mg + folic acid 550 mcg), capsules, oral suspensions like Acolate DS (paracetamol 250 mg + phenylephrine hydrochloride 5 mg + chlorpheniramine maleate 2 mg / 5 ml), injections such as Cesafe-TZ (ceftriaxone sodium 500 mg + tazobactam sodium 62.50 mg), ointments, and ayurvedic specialties including Instalins and Urikal Syrup. The company, founded in 1985 and headquartered in Ahmedabad, Gujarat, India, operates an ISO 9001-certified, fully automated manufacturing facility compliant with international regulatory standards and maintains a strong domestic presence across 13 Indian states alongside exports to emerging markets in Eastern and Western Africa, ASEAN countries, and LATAM regions. Recent developments include the installation of a new state-of-the-art mixing and branding machine with 200kg/lot capacity to enhance production capabilities, significant financial growth with EBITDA rising 114%, cash profit increasing 101%, and EPS up 94% as reported in recent periods, alongside ongoing new product launches and R&D investments in promising pipeline products to address unfulfilled healthcare needs; the company also held its 40th Annual General Meeting in August 2025 and continues to prioritize secondary sales growth, inventory optimization, and collection efficiency for sustainable expansion.